SCHEMBL20710493

SCHEMBL20710493

CN(CCOc1ccccc1)c1cc(N2CCC(O)CC2)nc(-c2cccnc2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 14/20 0.52
▸ KDM6B O15054 1/20 0.40
▸ NR1I2 O75469 1/20 0.40
▸ CHRNA1 P02708 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ OPRM1 P35372 1/20 0.40
▸ AHR P35869 1/20 0.40
▸ AVPR1A P37288 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ SCN5A Q14524 1/20 0.40
▸ KDM2B Q8NHM5 1/20 0.40
▸ KDM4C Q9H3R0 1/20 0.40
▸ KDM5B Q9UGL1 1/20 0.40
▸ PHF8 Q9UPP1 1/20 0.40
▸ SLCO1B1 Q9Y6L6 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ ROS1 P08922 1/20 0.39
▸ PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20710491 0.95 GBA1 (0.51) GBA1USP2ALDH1A1ROS1
SCHEMBL20710489 0.95 GBA1 (0.51) GBA1USP2ALDH1A1ROS1
SCHEMBL20710429 0.91 GBA1 (0.51) GBA1KDM6BNR1I2CHRNA1MAOB
SCHEMBL20710490 0.91 GBA1 (0.54) GBA1USP2ALDH1A1ROS1
SCHEMBL20710424 0.88 GBA1 (0.54) GBA1ALDH1A1ROS1CYP3A4CYP2C9
SCHEMBL20710517 0.81 GBA1 (0.46) GBA1MAOBALDH1A1CYP2D6
SCHEMBL22403212 0.81 GBA1 (0.52) GBA1USP2ALDH1A1
SCHEMBL20710471 0.80 GBA1 (0.65) GBA1USP2ALDH1A1
SCHEMBL20710506 0.80 GBA1 (0.65) GBA1USP2ALDH1A1
SCHEMBL28895045 0.78 ROS1 (0.44) GBA1ROS1PIM1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200283444-A1 SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF NORTHWESTERN UNIVERSITY 2020-09-10 — — US disclosed
WO-2019027765-A1 SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THERE NORTHWESTERN UNIVERSITY (US) 2019-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283444-A1 SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF GBA3, GBA1, GBA2 GBA1 2/4885KDM6B 2509/4885NR1I2 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback